Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation

Current Medical Research and Opinion

Volumn 27, Issue 12, 2011, Pages 2271-2278

  Matson, Mark A ^a   Zimmerman, Thomas R ^b   Tuccillo, Dianne ^b   Tang, Yongqiang ^b   Deykin, Aaron ^b  

^a PRISM Research Inc   (United States)

^b BIOGEN   (United States)

Author keywords

Flu like symptoms; Intramuscular interferon beta 1a; Multiple sclerosis; Safety; Titration; Treatment initiation

Indexed keywords

BETA1A INTERFERON; PARACETAMOL;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY TEMPERATURE; CHILL; CLINICAL EVALUATION; COLD SENSATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEART RATE; HUMAN; INCIDENCE; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALE; MOUTH HERPES; MOUTH INFECTION; MUSCLE SPASM; MYALGIA; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; OROPHARYNGEAL PAIN; PAIN; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TREATMENT DURATION; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; INFLUENZA, HUMAN; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 81855180715     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.630720     Document Type: Article

References (19)

1. Moses Jr H, Brandes DW. Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. Curr Med Res Opin 2008;24:2679-90
2. Girouard N, Théorê t G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs 2008;30:18-25
3. Bayas A, Rieckmann P. Managing the adverse effects of interferon-therapy in multiple sclerosis. Drug Safety 2000;22:149-59
4. Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8: 227-36
5. Brandes D, Bigley K, Hornstein W, et al. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study. Curr Med Res Opin 2007;23:1667-72
6. Wroe SJ. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 2005;33:309-18
7. Pelletier J. Open-Label, randomised, parallel group study of Rebif 44 mcg administered 3 times weekly with or without initial titration in relapsing-remitting multiple sclerosis patients previously treated with lowdose interferon beta therapy. Presented at European Committee for Treatment and Research in Multiple Sclerosis 21st Congress; 28 September-1 October 2005; Thessaloniki, Greece. Poster 302
8. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-94
9. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904
10. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-84
11. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon 1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002;59:1496-506
12. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
13. Avonex [prescribing information]; Cambridge, MA, USA: Biogen Idec Inc., 2008
14. Who gets MS?. National MS Society. New York: National Multiple Sclerosis Society, 2011. Available at: http://www.nationalmssociety.org/aboutmultiple- sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx [Last accessed 14 July 2011]
15. Clarke J. Mechanisms of adverse drug reactions to biologics. In: Hofmann FB, Ganten D, Page CP Handbook of Experimental Pharmacology. Berlin and New York: Springer-Verlag, 2010. Vol. 196, part 3, 453-74
16. Margolis K, Nichol KL, Poland GE, et al. Frequency of adverse reactions after influenza vaccination. Am J Med 1990;88:27-30
17. Nadjar Y, Coutelas E, Prouteau P, et al. Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis. Clin Neurol Neurosurg 2011;113:316-22
18. Ali A, Owayed S, Al-Qabandi W, et al. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotyple 4 in adolescents. Ann Hepatol 2010;9:156-60
19. Jara P, Hierro L, de al Vega A, et al. Efficacy and safety of peginterferon-a2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8